CIK cell therapy for B-cell leukemia after CAR-T failure
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell acute lymphoblastic leukemia that came back or did not respond to treatment.
- Your CAR-T cell therapy stopped working within the past 6 months, but you have not relapsed yet.
- You are between 1 and 39 years old.
- You are in generally good health (able to do daily activities) and expected to live at least 2 months.
- You do not have other active cancers, severe infections, or serious organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy (KITE-753) for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to previous treatments. The therapy uses your own immune cells, modified to find and attack leukemia cells, and may offer a new option when standard treatments have stopped working.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on leukemia cells. It's designed for people with relapsed or refractory B-cell acute lymphoblastic leukemia (a type of blood cancer) that hasn't responded to standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) that uses donor cells to target and kill leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has not responded to at least two prior treatments.
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.